Pdl Biopharma Inc (NASDAQ:PDLI) Shorted Shares Increased 2.96% After Market Selling

August 9, 2018 - By Margaret Guttierez

PDL BioPharma, Inc. (NASDAQ:PDLI) Logo

Investors sentiment decreased to 0.78 in 2018 Q1. Its down 0.35, from 1.13 in 2017Q4. It dropped, as 18 investors sold PDL BioPharma, Inc. shares while 56 reduced holdings. 20 funds opened positions while 38 raised stakes. 129.11 million shares or 4.07% less from 134.59 million shares in 2017Q4 were reported.
Geode Capital Mgmt Lc has 1.98 million shares for 0% of their portfolio. Moreover, Systematic Fincl Mgmt L P has 0.04% invested in PDL BioPharma, Inc. (NASDAQ:PDLI) for 567,795 shares. Fincl Architects Inc accumulated 0% or 3,500 shares. Tci Wealth Advisors reported 295 shares or 0% of all its holdings. Moreover, Jane Street Grp Ltd Com has 0% invested in PDL BioPharma, Inc. (NASDAQ:PDLI). Credit Suisse Ag, Switzerland-based fund reported 250,858 shares. Element Mgmt Limited Liability Com reported 0.01% in PDL BioPharma, Inc. (NASDAQ:PDLI). The New York-based Goldman Sachs Gp has invested 0% in PDL BioPharma, Inc. (NASDAQ:PDLI). Art Ltd Company has 0.02% invested in PDL BioPharma, Inc. (NASDAQ:PDLI) for 150,099 shares. Whittier Trust Of Nevada stated it has 80 shares. Pub Employees Retirement Association Of Colorado accumulated 57,000 shares or 0% of the stock. Prudential owns 0% invested in PDL BioPharma, Inc. (NASDAQ:PDLI) for 760,461 shares. First Republic Investment Mngmt accumulated 0% or 142,097 shares. Huntington Comml Bank reported 0% stake. Howe Rusling invested 0% in PDL BioPharma, Inc. (NASDAQ:PDLI).

The stock of Pdl Biopharma Inc (NASDAQ:PDLI) registered an increase of 2.96% in short interest. PDLI’s total short interest was 17.99M shares in August as published by FINRA. Its up 2.96% from 17.47M shares, reported previously. With 1.08 million shares average volume, it will take short sellers 17 days to cover their PDLI’s short positions. The short interest to Pdl Biopharma Inc’s float is 12.92%.

The stock decreased 5.93% or $0.15 during the last trading session, reaching $2.38. About 1.76 million shares traded or 11.16% up from the average. PDL BioPharma, Inc. (NASDAQ:PDLI) has risen 20.09% since August 9, 2017 and is uptrending. It has outperformed by 7.52% the S&P500.

PDL BioPharma, Inc. acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company has market cap of $358.53 million. The firm operates through two divisions, Income Generating Assets and Product Sales. It has a 3.45 P/E ratio. The Income Generating Assets segment consists of royalties from issued patents covering the humanization of antibodies, including Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, and Tysabri; and notes and other long-term receivables, royalty rights, hybrid notes/royalties receivable, and equity investments in healthcare companies.

More recent PDL BioPharma, Inc. (NASDAQ:PDLI) news were published by: Seekingalpha.com which released: “PDL Biopharma: Sum-Of-The-Parts Analysis Suggests Downside Protection, And Optionality On Private Equity …” on July 27, 2018. Also Seekingalpha.com published the news titled: “PDL BioPharma Inc. (PDLI) CEO John McLaughlin on Q2 2018 Results – Earnings Call Transcript” on August 09, 2018. Benzinga.com‘s news article titled: “The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos’ Maiden Earnings, Paratek Awaits Adcom Verdict” with publication date: August 08, 2018 was also an interesting one.

PDL BioPharma, Inc. (NASDAQ:PDLI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.